STERIS plc provides healthcare and life sciences products and services that support patient care, with an emphasis on infection prevention. Its recurring news includes financial results and outlook updates for continuing operations, quarterly dividend actions, conference-call announcements, and board or executive governance changes.
The company’s business updates center on sterilization services, Applied Sterilization Technologies, sterilizers, washer-disinfectors, and decontamination equipment and supplies used by care providers and biopharma manufacturing sites. Corporate announcements also address capital spending, cash flow expectations, and shareholder distribution information.
STERIS (NYSE: STE) reported fiscal 2027 second-quarter revenue of $1.6 billion, up 9% from the same quarter a year earlier. For the quarter ended September 30, 2026, reported diluted earnings per share rose to $2.19 from $1.94; adjusted diluted earnings per share increased to $2.94 from $2.47. Revenue grew 9% in Healthcare, 5% in Applied Sterilization Technologies and 18% in Life Sciences.
STERIS now expects fiscal 2027 adjusted diluted earnings per share of $11.35–$11.55, versus $11.10–$11.30 previously, including approximately $0.18 from tariff refunds received year-to-date. Revenue growth expectations remain 7–8%. First-half operating cash flow fell to $656.1 million from $707.8 million. A newly approved restructuring plan carries anticipated charges of approximately $45 million. The company lowered its organic growth outlook for Applied Sterilization Technologies and raised it for Life Sciences.
Stora Enso (STE) will ask shareholders on 15 December 2026 to approve separating its Swedish forest assets business into Bergslagets Skogar. The proposed cross-border partial demerger would transfer the business's related assets, rights, debts and liabilities to the new Swedish company. Completion is planned for 31 March 2027, although the date may change.
Shareholders would receive one Bergslagets Skogar share for each Stora Enso share: class A holders would receive class A shares, and class R holders would receive class B shares. Distribution would be automatic. Applications for trading on Nasdaq Stockholm and Nasdaq Helsinki are intended. Approval requires two-thirds of votes cast and shares represented, including within each represented share class. Shareholders can approve or reject the plan but cannot amend it.
STERIS (NYSE: STE) announced a quarterly dividend of $0.69 per share, payable to shareholders on December 17, 2026. Shareholders must be on record at the close of business on November 17, 2026. Information about U.S. dividend tax treatment, including required Forms 8937, is available at www.steris-ir.com.
CooperCompanies (COO) elected Walt Rosebrough Executive Chair, with direct oversight of daily operations while the company searches for a permanent CEO. Al White stepped down immediately as President, CEO and a director. Rosebrough said recent performance had not met expectations and the Board believed action was needed.
Shlomi Nachman will join as an independent director on December 8, 2026. Barbara Carbone, Colleen Jay and Robert Weiss intend not to seek reelection at the 2027 annual meeting, where the Board will nominate seven directors. Russell Reynolds is supporting the CEO search, overseen by a Board committee. The company also reaffirmed its full-year guidance.
STERIS (STE) will host a conference call on November 5, 2026, to discuss its fiscal 2027 second quarter results. The call begins at 9:00 a.m. ET, following the results release after the U.S. market closes on November 4, 2026. A replay will be available beginning at 12:00 p.m. ET on November 5.
Xodus Medical has entered into an agreement to be acquired by STERIS (NYSE: STE), combining their surgical safety offerings through the proposed acquisition.
Xodus Medical expects joining a larger global organization to expand its reach and strengthen its ability to support healthcare providers. STERIS said Xodus Medical's portfolio complements its offerings, particularly by adding consumables used in operating rooms. Goldman Sachs and Jones Day are advising STERIS; J.P. Morgan and Morgan, Lewis & Bockius are advising Xodus Medical.
STERIS (NYSE: STE) has signed a definitive agreement through its wholly owned subsidiary to acquire Xodus Medical for $2.1 billion at closing. STERIS Corporation will acquire all equity of the specialty surgical products business and certain related affiliates, expanding its operating-room consumables offering.
STERIS anticipates cash tax benefits with a net present value of approximately $300 million, resulting in a net purchase price of approximately $1.8 billion. The price is subject to customary adjustments, plus potential earnout consideration of up to $150 million tied to specified calendar 2028 performance targets.
STERIS expects primarily debt financing and closing by December 31, 2026, subject to regulatory approvals and customary closing conditions. The company expects the acquisition to be accretive to revenue growth, margins and adjusted earnings.
STERIS (NYSE: STE) will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026. President and CEO Dan Carestio is scheduled to present at 1:05 p.m. Eastern Time. A live webcast and replay of the presentation will be available on the STERIS investor relations website at www.steris-ir.com.
STERIS (NYSE: STE) reported fiscal 2027 first quarter revenue of $1.5 billion, up 7% year over year, with constant currency organic revenue growth of 6%. As reported diluted EPS rose to $2.04 from $1.79, while adjusted EPS increased to $2.59 from $2.34.
Healthcare revenue grew 8% to $1.05 billion, AST rose 6% to $297.6 million, and Life Sciences increased 9% to $146.7 million. Operating income improved across all segments. Net cash from operations declined to $367.1 million and free cash flow to $279.6 million, mainly due to lower working capital contribution.
STERIS announced a targeted restructuring tied to consolidating formulated chemistries into a new North Carolina Center of Excellence, expecting $55–$70 million pre-tax charges through fiscal 2030 and eventual closure of facilities in Missouri and Minnesota. The company reaffirmed fiscal 2027 guidance for 7–8% reported revenue growth, 6–7% constant currency organic growth, and adjusted EPS of $11.10–$11.30. Capital expenditures are now projected at $450 million and free cash flow at about $800 million.
STERIS (NYSE: STE) will invest $600 million to build a formulated chemistries manufacturing and distribution Center of Excellence in North Carolina near the Raleigh-Durham Research Triangle. The 600,000 square-foot campus will produce infection prevention and contamination control chemistries for Healthcare and Pharmaceutical customers.
The project will be constructed in phases and is expected to become operational in 2–3 years, beginning with distribution. According to STERIS, the site will ultimately replace existing chemistries manufacturing and distribution operations in St. Louis, Missouri and Plymouth, Minnesota and create about 335 jobs in North Carolina.